



20th KM Hosur Road, Electronics City, Bangalore 560 100

Bangalore, January 14, 2019

Biocon's Q3 FY 2018-19 Results Conference Call

At 9.00 am IST on January 25, 2019

Biocon Limited (BSE code: 532523, NSE Id: BIOCON) will announce results for the third quarter of FY 2018-19, ended December 31, 2018 on January 24, 2019. Following the announcement, the management of Biocon Limited will host an earnings call to discuss the Company's performance on January 25, 2019.

Details of the conference call are as under:

Date:	Friday, January 25, 2019
Time:	9.00 am IST
Duration:	60 minutes
Dial-in Numbers:	
Participation are encouraged to dial in 10 minutes prior to the call start to avoid hold times at the last minute. If you reach on operator during the dial in process please inform the operator that you would like to join " Biocon Ltd. Q3 FY19 Earnings Conference Call "	
Universal Access numbers	+91 22 6280 1151 +91 22 7115 8052
Local Access (All India)	+91 70456 71221
International Local Access Numbers	USA: +1 323 386 8721 UK: +44 20 3478 5524 Singapore: +65 3157 5746 Hong Kong: +852 3018 6877
Pre-Registration Facility	<ul style="list-style-type: none">• Step 1: Pre-register here. You will receive an email confirmation with the call details on the registered email address• Step 2: Dial into the call on the Conference Call date, you are directly connected to the call
Replay Facility	The replay will be available 60 minutes after the earnings call ends. Dial in number: +91 22 7194 5757 or +91 22 6663 5757, Playback Code: 25346 Replay available till February 1, 2019
Transcript	Will be made available after a few days on the Company's website

Please note: This call is not open to the members of the media (print/online)

About Biocon

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 120 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from 'Lab to Market'. Some of its key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), BIOMAb-EGFR™ (Nimotuzumab), CANMAb™ (Trastuzumab), Evertor® (Everolimus) and ALZUMAb™ (Itolizumab), a 'first in class' anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin. www.biocon.com follow-us on twitter: @bioconlimited

Contact:

For further information please contact:

Saurabh Paliwal

Investor Relations – Biocon Limited

☎ +91 80 6775 2040

✉: investor.relations@biocon.com

Diwakar Pingle

Christensen Investor Relations

☎: +91 22 4215 0210

✉: dpingle@ChristensenIR.com

Safe Harbor: *Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current assumptions and expectations concerning future developments and their potential effects upon Biocon and its subsidiaries/associates. There can be no assurance that future developments affecting Biocon and its subsidiaries/associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties that may cause actual results to differ, possibly materially, from those contemplated by such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our subsidiaries/ associates have any obligation to update or otherwise revise any statements reflecting circumstances arising after conclusion of the conference call to reflect the occurrence of underlying events, even if the underlying assumptions and expectations do not come to fruition.*